[Form 4] TTEC Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Item 5.02 8-K: On 18 Jul 2025 Lixte Biotechnology appointed Jason Sawyer and Dr. Michael Holloway as independent directors under designation rights granted to investors that bought 3,573,190 Series B Preferred Shares on 3 Jul 2025. Sawyer also becomes Chair of the Compensation Committee and joins the Audit Committee.

To accommodate the appointments, Dr. Stephen Forman and Dr. Yun Yen resigned from the Board and moved to the company’s Scientific Advisory Committee. The company states these departures were not due to disagreements.

Separately, Chief Medical Officer Dr. Jan Schellens tendered his resignation and his consulting agreement will end 31 Jul 2025 so he can pursue other opportunities; no disputes were cited.

No financial results, guidance, or operational metrics were provided—this filing is strictly a corporate-governance update linked to the recent preferred-equity financing.

Positive

• Preferred-shareholder representation adds two independent directors, potentially strengthening oversight and aligning new capital with governance.
• Reassignment of departing directors to the Scientific Advisory Committee retains domain expertise, limiting knowledge loss.

Negative

• Chief Medical Officer resignation may slow clinical development and poses leadership continuity risk.
• Multiple board departures in a short window can create strategic uncertainty and distract management.

Insights

Corporate Governance Expert

TL;DR: Board expands to include preferred-shareholder nominees; independent oversight rises, but key executive exits.

The Series B investors have swiftly exercised their right to place two nominees on the Board, increasing shareholder representation and potentially improving governance. Sawyer’s instant elevation to Compensation Committee chair implies influence over pay policy. Reassignment of Forman and Yen to the Scientific Advisory Committee preserves institutional knowledge, mitigating disruption. However, simultaneous turnover of three directors plus the CMO creates near-term execution risk. Overall impact appears balanced.

Biotech Sector Analyst

TL;DR: Governance shuffle after financing; CMO departure raises pipeline execution questions.

Adding investor-backed directors may speed strategic decisions and signal confidence from new capital. Yet losing the CMO during clinical development could delay trials, require recruiting costs, and unsettle partner discussions. Because no programs were referenced, the operational effect is uncertain but potentially negative if replacement lags. Net impact: neutral-to-slightly negative until a suitable scientific leader is hired.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Abou John P.

(Last) (First) (Middle)

100 CONGRESS AVENUE

SUITE 1425

(Street)

AUSTIN TX 78701

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TTEC Holdings, Inc. [ TTEC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, TTEC Engage

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	07/17/2025		M		19,480	A	$0	19,480	D
Common Stock(2)	07/17/2025		F		7,023	D	$4.97	12,457	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units(1)	$0	07/17/2025		M			19,480	(1)	(1)	Common Stock	19,480	$0	77,923	D

Explanation of Responses:

1. Reflects vesting of Restricted Stock Units ("RSUs") on July 17, 2025. The Reporting Person initially received 97,403 time-based RSUs on July 17, 2024. The RSUs vest in five installments of 20% per year beginning on July 17, 2025.

2. Reflects withholding of shares to satisfy tax obligations in connection with the vesting of RSUs. No shares were sold.

	/s/ Margaret B. McLean, Attorney-in-Fact for John P. Abou	07/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why did LIXT file an 8-K on 21 Jul 2025?

The company reported board changes, including the appointment of two new independent directors and resignation of its Chief Medical Officer.

Who are the new directors of Lixte Biotechnology (LIXT)?

Jason Sawyer and Dr. Michael Holloway were appointed on 18 Jul 2025 under rights held by Series B Preferred shareholders.

Did any directors resign from LIXT?

Yes. Dr. Stephen Forman and Dr. Yun Yen resigned from the Board but joined the Scientific Advisory Committee.

What committees will Jason Sawyer join?

Sawyer becomes Chairman of the Compensation Committee and a member of the Audit Committee.

When does CMO Dr. Jan Schellens leave LIXT?

His resignation and consulting agreement termination are effective 31 Jul 2025.

Were the resignations due to disagreements with the company?

The filing states that none of the resignations resulted from disagreements over operations, policies, or practices.